Showing results (311-320 of 324) with videos related to
Sort By:
Pageof 33
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 28, 2026
Consensus statement on ctDNA minimal residual disease (MRD) testing in early-stage NSCLC - A Delphi study by the Asian Thoracic Oncology Research Group (ATORG)Aaron C Tan, Bin-Chi Liao, Molly Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical PracticeXiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSASe-Hoon Lee, Shun Lu, Hidetoshi Hayashi, et al.American Journal of Respiratory and Critical Care Medicine|September 27, 2016
Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase InhibitorsI-Shou Chang, Shih Sheng Jiang, James Chih-Hsin Yang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 18, 2025
Amivantamab in Participants with Advanced Non-small Cell Lung Cancer (NSCLC) and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS StudyMatthew G Krebs, Byoung Chul Cho, Sandrine Hiret, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2021
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I StudyKeunchil Park, Eric B Haura, Natasha B Leighl, et al.European Journal of Cancer (Oxford, England : 1990)|July 29, 2025
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 studyMariam Alexander, Ying Cheng, Se-Hoon Lee, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.Pageof 33